Moderate

Patent foramen ovale & cryptogenic stroke

PFO and paradoxical embolism · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A patent foramen ovale is a common interatrial communication that can permit paradoxical embolism. In selected younger patients with cryptogenic stroke and a high-risk PFO, device closure reduces recurrent stroke compared with medical therapy alone.

Red flags

  • Recurrent stroke despite therapy
  • New atrial fibrillation detected on monitoring
  • Evidence of deep vein thrombosis with PFO
  • Large shunt with atrial septal aneurysm
  • Stroke in an older patient (reconsider mechanism)

Assessment

Differential diagnosis

  • Atrial septal defect
  • Atherosclerotic/large-vessel stroke
  • Small-vessel (lacunar) stroke
  • Cardioembolic stroke from AF
  • Dissection-related stroke
  • Hypercoagulable-state embolism

Investigations

  • Transthoracic/transoesophageal echo with bubble study (shunt, atrial septal aneurysm)
  • Prolonged ambulatory ECG to exclude occult atrial fibrillation
  • MRI brain to characterise infarct pattern
  • Carotid/intracranial vascular imaging
  • Thrombophilia screen in selected younger patients
  • Lower-limb venous imaging if DVT suspected

Management

  • Confirm the stroke is cryptogenic after thorough workup
  • Exclude atrial fibrillation with prolonged rhythm monitoring
  • Identify high-risk PFO features (large shunt, atrial septal aneurysm)
  • Apply a validated causality assessment (e.g. RoPE score) in younger patients
  • Discuss PFO closure in patients under ~60 with otherwise cryptogenic embolic stroke and high-risk PFO
  • Proceed to percutaneous device closure in appropriate candidates
  • Prescribe antiplatelet therapy after closure
  • Use anticoagulation if a separate indication (e.g. DVT, thrombophilia) exists
  • Avoid closure when another clear stroke mechanism is identified
  • Counsel on the balance of recurrent stroke reduction versus new atrial fibrillation risk
  • Coordinate neurology and cardiology shared decision-making
  • Arrange echo follow-up for residual shunt

Drugs & doses

Aspirin 75-100 mg PO OD (antiplatelet after closure or medical therapy)
Clopidogrel 75 mg PO OD (added short-term after device, or alternative)
Apixaban 5 mg PO BD if a separate anticoagulation indication exists
No routine anticoagulation for isolated PFO without another indication

Disposition

Joint neurology and cardiology (ACHD/structural) decision; device closure in selected patients with specialist follow-up.

Complications & pitfalls

  • Recurrent paradoxical embolism
  • New-onset atrial fibrillation after device closure
  • Device-related thrombus or erosion
  • Residual shunt
  • Bleeding from antithrombotic therapy

Exam pearls

  • PFO closure benefits are clearest in patients under 60 with high-risk anatomy and no competing stroke cause
  • Device closure carries a small risk of new atrial fibrillation — usually transient
  • A right-to-left shunt on bubble study supports a paradoxical mechanism
  • Closure is not indicated for incidental PFO without embolic events
  • Exclude occult AF before attributing stroke to a PFO

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.